Casirivimab (REGN10933) is a human monoclonal antibody designed to specifically target the SARS-CoV-2 virus, responsible for COVID-19. This antibody has shown limitations in its efficacy against emerging COVID-19 variants. For enhanced therapeutic potential, Casirivimab can be administered in conjunction with Imdevimab. This combination has been demonstrated to modify the pulmonary response in K18-hACE2 transgenic mice infected with the SARS-CoV-2 ?? variant, leading to a significant reduction in viral load and amelioration of clinical symptoms.
Casirivimab (REGN10933) is a human monoclonal antibody designed to specifically target the SARS-CoV-2 virus, responsible for COVID-19. This antibody has shown limitations in its efficacy against emerging COVID-19 variants. For enhanced therapeutic potential, Casirivimab can be administered in conjunction with Imdevimab. This combination has been demonstrated to modify the pulmonary response in K18-hACE2 transgenic mice infected with the SARS-CoV-2 ?? variant, leading to a significant reduction in viral load and amelioration of clinical symptoms.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
